Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ...
Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk ...
Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's ...
Abbott (NYSE:ABT) today shared new study findings supporting its pulsed field ablation (PFA) and conduction system pacing ...
Heart disease is becoming increasingly common today. We know that the heart has its own electrical system that regulates its rhythm. When there is a “heart block,” the signal is disrupted — the heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results